Thromb Haemost 1990; 64(03): 473-477
DOI: 10.1055/s-0038-1647339
Original Article
Schattauer GmbH Stuttgart

Chlorobutanol, a Preservative of Desmopressin, Inhibits Human Platelet Aggregation and Release In Vitro

Shih-Luen Chen
The Section of Nephrology, Department of Internal Medicine, Veterans General Hospital Taipei, Taipei, Taiwan
,
Wu-Chang Yang
The Section of Nephrology, Department of Internal Medicine, Veterans General Hospital Taipei, Taipei, Taiwan
,
Tung-Po Huang
The Section of Nephrology, Department of Internal Medicine, Veterans General Hospital Taipei, Taipei, Taiwan
,
Shiang Wann
The Section of Nephrology, Department of Internal Medicine, Veterans General Hospital Taipei, Taipei, Taiwan
,
Che-ming Teng
*  The Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan
› Author Affiliations
Further Information

Publication History

Received: 07 October 1989

Accepted after revision02 July 1990

Publication Date:
25 July 2018 (online)

Summary

Therapeutic preparations of desmopressin for parenteral use contain the preservative chlorobutanol (5 mg/ml). We show here that chlorobutanol is a potent inhibitor of platelet aggregation and release. It exhibited a significant inhibitory activity toward several aggregation inducers in a concentration- and time-dependent manner. Thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin respectively were markedly inhibited by chlorobutanol. Chlorobutanol had no effect on elastase- treated platelets and its antiplatelet effect could be reversed. It is concluded that the antiplatelet effect of chlorobutanol is mainly due to its inhibition on the arachidonic acid pathway but it is unlikely to have a nonspecitic toxic effect. This antiplatelet effect of chlorobutanol suggests that desmopressin, when administered for improving hemostasis, should not contain chlorobutanol as a preservative.